Company news
Lobe Sciences Ltd news in 2023
Lobe Sciences Ltd's news releases, calls and decks from 2023, newest first.
Lobe Sciences Provides Update on L-130 Clinical Program
December 7, 2023
Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
June 30, 2023
Lobe Sciences, Ltd. Provides Update on Vitamind
April 21, 2023
Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company
April 18, 2023
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
April 4, 2023
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
March 22, 2023
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
March 1, 2023
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC
February 21, 2023
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance
February 10, 2023
Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
February 6, 2023
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees
January 23, 2023
Lobe Sciences Provides Update For 2023 Milestones
January 18, 2023
Trippy Trading: Top Psychedelic Stocks For 2023
January 17, 2023